COVID-19 pandemic in Lakshadweep
The first case of COVID-19 on the Union Territory Lakshadweep was recorded on 18 January 2021 on the islands.[1] Lakshadweep Islands, until then, was India's only COVID-free territory (state/UT), and life was pretty normal for the residents of the UT.[2]
COVID-19 pandemic in the Lakshadweep Islands | |
---|---|
Disease | COVID-19 |
Virus strain | SARS-CoV-2 |
Location | Lakshadweep Islands, India |
First outbreak | Wuhan, Hubei, China |
Arrival date | 18 January 2021 (3 weeks) |
There are 30 total cases reported in the UT as of 21 January 2021.[3]
Statistics
District | Total cases | Recoveries | Deaths | Active cases |
---|---|---|---|---|
Total | 153 | 63 | 0 | 90 |
Lakshadweep | 153 | 63 | 0 | 90 |
As of 2021-02-07[4] |
Timeline
January 2021
- As on 19 January, total number of cases in Lakshadweep was 21. All of them are active cases.[3]
- As on 20 January, total number of cases was 30. All of them are active cases.[3]
- As on 21 January, total number of cases was 48. All of them are active cases.[3]
- As on 22 January, total number of cases was 50. All of them are active cases.[3]
- As on 24 January, total number of cases in the UT was 57. All of them are active cases.[3]
- As on 25 January, total number of cases was 67. All of them are active cases.[3]
- As on 27 January, total number of cases was 69. All of them are active cases.[3]
February 2021
- As on 1 February, total number of cases in Lakshadweep was 99, including 43 active cases and 56 recoveries.[3]
- As on 2 February, total number of cases was 119, including 56 active cases and 63 recoveries.[3]
- As on 3 February, total number of cases was 122, including 61 active cases and 61 recoveries.[3]
COVID-19 vaccines with approval for emergency or conditional usage
Covishield
On 1 January 2021, the Drug Controller General of India, approved the emergency or conditional use of AstraZeneca’s COVID-19 vaccine AZD1222 (marketed as Covishield).[5] Covishield is developed by the University of Oxford and its spin-out company, Vaccitech.[6] It's a viral vector vaccine based on replication-deficient Adenovirus that causes cold in Chimpanzees. It can be stored, transported and handled at normal refrigerated conditions (two-eight degrees Celsius/ 36-46 degrees Fahrenheit). It has a shelf-life of at least six months.
On 12 January 2021, the first batches of Covishield vaccine were dispatched from the Serum Institute of India.[7]
Covaxin
On 2 January 2021, BBV152 (marketed as Covaxin), first indigenous vaccine, developed by Bharat Biotech in association with the Indian Council of Medical Research and National Institute of Virology received approval from the Drug Controller General of India for its emergency or conditional usage.[8]
On 14 January 2021, the first batches of Covaxin vaccine were dispatched from Bharat Biotech, albeit still in the third phase of testing.[9]
References
- "Nearly a year after Covid-19 outbreak in India, Lakshadweep reports its first-ever case". India Today. Retrieved 22 January 2021.
- "What Covid-19? Life is normal is Lakshadweep". Times of India. Retrieved 22 January 2021.
- "MoHFW-Home". www.mohfw.gov.in. Retrieved 22 January 2021.
- "COVID cases source". Retrieved 7 February 2021.
- "COVID-19 vaccine Covishield gets approval from DCGI's expert panel". The Hindu. 1 January 2021. Retrieved 22 January 2021.
- "AstraZeneca's COVID-19 vaccine authorised for emergency supply in the UK". AstraZeneca. AstraZeneca. 30 December 2020. Retrieved 22 January 2021.
- "Stand By, India: Serum Institute Sends Out Vaccines, 1st Batch In Delhi". NDTV. 12 January 2021. Retrieved 22 January 2021.
- "Expert panel recommends Bharat Biotech's Covaxin for restricted emergency use". News18. 2 January 2021. Retrieved 22 January 2021.
- "Covaxin delivery starts, 'full initial procurement allotted'". Indian Express. 14 January 2021. Retrieved 22 January 2021.